Kurzfassung

Although new antibiotics against methicillin-resistant Staphylococcus aureus (MRSA, a major nosocomial pathogen) have been developed in recent years, this bacterium remains a difficult to treat infection in humans. It continues to be a troubling problem since it most often occurs in hospitals and healthcare facilities. It is one of the main contributors to nosocomial morbidity and mortality. Ceftaroline is an advanced-generation cephalosporin antibiotic which combines an efficacy against MRSA...Although new antibiotics against methicillin-resistant Staphylococcus aureus (MRSA, a major nosocomial pathogen) have been developed in recent years, this bacterium remains a difficult to treat infection in humans. It continues to be a troubling problem since it most often occurs in hospitals and healthcare facilities. It is one of the main contributors to nosocomial morbidity and mortality. Ceftaroline is an advanced-generation cephalosporin antibiotic which combines an efficacy against MRSA with the outstanding pharmacokinetic and pharmacodynamic properties of all cephalosporines as a beta-lactam antibiotic. As a result of this, ceftaroline could have extensive application possibilities, e.g. for treating pneumonia or skin and soft tissue infections (SSTI).

The study will focus on the in vitro efficacy of ceftaroline in Methicillin-resistant Staphylococcus aureus. The susceptibility for vancomycin, daptomycine and linelozid will also be determined for comparative reasons. 600 clinically relevant MRSA strains will be tested. Several certified reference strains as well as twenty clinical methicillin-susceptible Staphylococcus aureus isolates shall be used as controls.» weiterlesen» einklappen